Evidence map›Paper›PMID 34242123›Full record

ArticleHuman vaccines & immunotherapeutics2022

SARS-CoV-2 vaccination in the context of original antigenic sin.

Marek Petráš, Ivana Králová Lesná

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marek PetrášDepartment of Epidemiology and Biostatistics, Charles University Third Faculty of Medicine, Prague, Czech Republic.ORCID 0000-0003-2913-1736
Ivana Králová LesnáCentre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.ORCID 0000-0002-9053-4123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunological memory is the ability of the adaptive immune system to ensure a persistent protective effect after immunization. However, it can also be a limitation to building a sufficient level of protective antibodies specific to new mutations of the virus. It is imperative to bear this phenomenon (called "original antigenic sin") in mind and make every effort to overcome its inherent pitfalls when updating current and designing new vaccines.

Indexed as

COVID-19SARS-CoV-2AntigensCOVID-19 VaccinesHumansVaccinationAntigensCOVID-19 VaccinesOriginal antigenic sinSARS-COV-2vaccination

Identifiers

PMID34242123
PMCPMC8290366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.